BeiGene Ltd (BGNE)
150.64
+6.52
(+4.52%)
USD |
NASDAQ |
Apr 25, 11:28
BeiGene Enterprise Value: 12.75B for April 24, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| April 24, 2024 | 12.75B |
| April 23, 2024 | 12.22B |
| April 22, 2024 | 11.38B |
| April 19, 2024 | 11.23B |
| April 18, 2024 | 11.48B |
| April 17, 2024 | 11.47B |
| April 16, 2024 | 11.70B |
| April 15, 2024 | 12.15B |
| April 12, 2024 | 12.46B |
| April 11, 2024 | 12.96B |
| April 10, 2024 | 13.34B |
| April 09, 2024 | 13.78B |
| April 08, 2024 | 13.34B |
| April 05, 2024 | 13.37B |
| April 04, 2024 | 13.32B |
| April 03, 2024 | 13.57B |
| April 02, 2024 | 13.70B |
| April 01, 2024 | 14.33B |
| March 28, 2024 | 14.03B |
| March 27, 2024 | 13.89B |
| March 26, 2024 | 13.76B |
| March 25, 2024 | 13.77B |
| March 22, 2024 | 13.57B |
| March 21, 2024 | 14.79B |
| March 20, 2024 | 15.41B |
| Date | Value |
|---|---|
| March 19, 2024 | 15.25B |
| March 18, 2024 | 15.29B |
| March 15, 2024 | 15.45B |
| March 14, 2024 | 15.34B |
| March 13, 2024 | 16.13B |
| March 12, 2024 | 14.80B |
| March 11, 2024 | 14.88B |
| March 08, 2024 | 14.25B |
| March 07, 2024 | 14.64B |
| March 06, 2024 | 14.36B |
| March 05, 2024 | 14.45B |
| March 04, 2024 | 15.23B |
| March 01, 2024 | 14.93B |
| February 29, 2024 | 15.00B |
| February 28, 2024 | 16.38B |
| February 27, 2024 | 16.51B |
| February 26, 2024 | 14.47B |
| February 23, 2024 | 13.93B |
| February 22, 2024 | 13.79B |
| February 21, 2024 | 13.48B |
| February 20, 2024 | 13.19B |
| February 16, 2024 | 13.21B |
| February 15, 2024 | 12.99B |
| February 14, 2024 | 12.97B |
| February 13, 2024 | 12.50B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
5.471B
Minimum
Jun 17 2019
33.75B
Maximum
Sep 17 2021
16.96B
Average
16.42B
Median
Nov 29 2023
Enterprise Value Benchmarks
| Theravance Biopharma Inc | 339.24M |
| LumiraDx Ltd | -- |
| ASLAN Pharmaceuticals Ltd | 15.98M |
| Zai Lab Ltd | 747.16M |
| Legend Biotech Corp | 7.190B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -367.55M |
| Revenue (Quarterly) | 634.41M |
| Total Expenses (Quarterly) | 1.018B |
| EPS Diluted (Quarterly) | -3.51 |
| Gross Profit Margin (Quarterly) | 83.32% |
| Profit Margin (Quarterly) | -57.94% |
| Earnings Yield | -5.70% |
| Normalized Earnings Yield | -5.696 |